Aliases & Classifications for Cardiac Arrhythmia

MalaCards integrated aliases for Cardiac Arrhythmia:

Name: Cardiac Arrhythmia 58 30 6 17
Adverse Event Associated with Cardiac Arrhythmia 74
Premature Cardiac Complex 74
Extrasystoles 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
cardiac arrhythmia:
Clinical modifier sudden death
Inheritance autosomal dominant inheritance


External Ids:

OMIM 58 115000
MedGen 43 C0003811
SNOMED-CT via HPO 70 263681008 26636000 88425004

Summaries for Cardiac Arrhythmia

MalaCards based summary : Cardiac Arrhythmia, also known as adverse event associated with cardiac arrhythmia, is related to cardiac conduction defect and long qt syndrome 13, and has symptoms including pulsus trigeminus and bigeminal pulse. An important gene associated with Cardiac Arrhythmia is TANGO2 (Transport And Golgi Organization 2 Homolog), and among its related pathways/superpathways are Circadian entrainment and Aldosterone synthesis and secretion. The drugs Methadone and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are abnormality of the nervous system and polymorphic and polytopic ventricular extrasystoles

Description from OMIM: 115000

Related Diseases for Cardiac Arrhythmia

Diseases related to Cardiac Arrhythmia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 276, show less)
# Related Disease Score Top Affiliating Genes
1 cardiac conduction defect 31.9 KCNH2 KCNQ1 RYR2 SCN5A
2 long qt syndrome 13 31.6 KCNH2 KCNQ1 SCN5A
3 long qt syndrome 9 31.6 KCNJ2 SCN5A
4 long qt syndrome 3 31.2 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
5 brugada syndrome 1 31.0 KCNH2 SCN5A
6 long qt syndrome 12 30.9 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
7 familial short qt syndrome 30.6 KCNH2 KCNJ2 KCNQ1
8 long qt syndrome 2 30.5 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
9 ventricular fibrillation, paroxysmal familial, 1 30.2 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1 RYR2
10 sudden infant death syndrome 30.2 KCNH2 KCNQ1 RYR2 SCN5A
11 syncope 30.0 KCNH2 KCNJ2 KCNQ1 SCN5A
12 long qt syndrome 5 30.0 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
13 sick sinus syndrome 30.0 CACNA1C RANGRF SCN5A
14 long qt syndrome 1 29.8 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
15 long qt syndrome 6 29.8 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
16 cardiac arrest 29.8 ANK2 KCNH2 KCNQ1 RYR2 SCN5A
17 brugada syndrome 29.6 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1
18 arrhythmogenic right ventricular cardiomyopathy 29.5 ANK2 KCNH2 RYR2 SCN5A
19 hypertrophic cardiomyopathy 29.5 CACNA1C RYR2 SCN5A
20 right bundle branch block 29.3 CACNA1C SCN5A
21 atrioventricular block 29.2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
22 catecholaminergic polymorphic ventricular tachycardia 29.1 ANK2 KCNH2 KCNJ2 RYR2 SCN5A
23 hypokalemic periodic paralysis, type 1 29.1 CACNA1C KCNJ2
24 heart disease 29.0 CACNA1C KCNE2 KCNH2 KCNJ2 KCNQ1 RYR2
25 dilated cardiomyopathy 28.8 CACNA1C KCNH2 KCNQ1 RYR2 SCN5A
26 atrial fibrillation 28.8 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
27 jervell and lange-nielsen syndrome 1 28.3 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
28 long qt syndrome 28.3 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
29 intellectual developmental disorder with cardiac arrhythmia 12.7
30 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 12.6
31 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 12.6
32 cardiac arrhythmia, ankyrin-b-related 12.6
33 extrasystoles, multiform ventricular, with short stature, hyperpigmentation and microcephaly 12.1
34 ventricular extrasystoles with syncope, perodactyly, and robin sequence 12.1
35 extrasystoles short stature hyperpigmentation microcephaly 12.1
36 muscular dystrophy, limb-girdle, autosomal recessive 25 12.0
37 ogden syndrome 11.8
38 tango2-related metabolic encephalopathy and arrhythmias 11.7
39 myotonic dystrophy 1 11.3
40 spondylometaphyseal dysplasia, sedaghatian type 11.3
41 hand and foot deformity with flat facies 11.2
42 carnitine palmitoyltransferase ii deficiency, lethal neonatal 11.2
43 thyrotoxic periodic paralysis 11.2
44 arrhythmogenic right ventricular dysplasia, familial, 1 11.0
45 refsum disease, classic 11.0
46 heterotaxy, visceral, 1, x-linked 11.0
47 cardiomyopathy, infantile histiocytoid 11.0
48 hypomagnesemia 1, intestinal 11.0
49 myotonic dystrophy 2 11.0
50 arrhythmogenic right ventricular dysplasia, familial, 8 11.0
51 long qt syndrome 11 11.0
52 ventricular fibrillation, paroxysmal familial, 2 11.0
53 glycogen storage disease xv 11.0
54 congenital heart defects, multiple types, 4 11.0
55 chronic atrial and intestinal dysrhythmia 11.0
56 congenital heart defects, multiple types, 5 11.0
57 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 5 11.0
58 his bundle tachycardia 11.0
59 renal tubular acidosis, distal 11.0
60 ventricular extrasystoles with syncopal episodes - perodactyly - robin sequence 11.0
61 myocardial infarction 10.5
62 brugada syndrome 2 10.4
63 brugada syndrome 3 10.4
64 brugada syndrome 4 10.4
65 brugada syndrome 5 10.4
66 brugada syndrome 6 10.4
67 brugada syndrome 7 10.4
68 brugada syndrome 8 10.4
69 torsade de pointes, short-coupled variant 10.4
70 cardiac conduction disease with or without dilated cardiomyopathy 10.4
71 brugada syndrome 9 10.4
72 ischemia 10.4
73 hypoglycemia 10.3
74 rere-related disorders 10.3
75 acute myocardial infarction 10.3
76 hypokalemia 10.3
77 familial sick sinus syndrome 10.3
78 idiopathic ventricular fibrillation, non brugada type 10.3
79 sleep apnea 10.3
80 left bundle branch hemiblock 10.2
81 third-degree atrioventricular block 10.2 KCNE2 SCN5A
82 esterase c 10.2
83 aging 10.1
84 congestive heart failure 10.1
85 epilepsy 10.1
86 atrial heart septal defect 10.1
87 benign neonatal seizures 10.1 KCNE2 KCNQ1
88 atrial standstill 1 10.1
89 thrombosis 10.1
90 glomerulonephritis 10.1
91 second-degree atrioventricular block 10.1
92 pyelonephritis 10.1
93 myasthenic syndrome, congenital, 5 10.1 KCNH2 RYR2
94 aplasia cutis congenita, nonsyndromic 10.0
95 orthostatic intolerance 10.0
96 pulmonary disease, chronic obstructive 10.0
97 liver disease 10.0
98 nonalcoholic fatty liver disease 10.0
99 respiratory failure 10.0
100 tuberous sclerosis 10.0
101 fatty liver disease 10.0
102 myotonic dystrophy 10.0
103 myotonia atrophica 10.0
104 rett syndrome 10.0
105 coronary heart disease 1 10.0
106 pulmonary hypertension 10.0
107 diabetes mellitus 10.0
108 heart valve disease 10.0
109 hypophosphatemia 10.0
110 intestinal volvulus 10.0
111 transposition of the great arteries 10.0
112 hypoxia 10.0
113 left ventricular noncompaction 10.0 KCNQ1 RYR2 SCN5A
114 atrioventricular dissociation 9.9
115 mental retardation, autosomal dominant 44 9.9
116 mobitz type ii atrioventricular block 9.9
117 mitral valve stenosis 9.9
118 microcephaly 9.9
119 broken heart syndrome 9.9
120 polymyositis 9.9
121 fainting 9.9
122 cardiogenic shock 9.9
123 apnea, obstructive sleep 9.9
124 arteries, anomalies of 9.9
125 hypertension, essential 9.9
126 hyperkalemic periodic paralysis 9.9
127 graves disease 1 9.9
128 fabry disease 9.9
129 anorexia nervosa 9.9
130 polyglucosan body myopathy 1 with or without immunodeficiency 9.9
131 brain injury 9.9
132 burns 9.9
133 coronary artery anomaly 9.9
134 ischemic heart disease 9.9
135 anhidrosis 9.9
136 coronary artery vasospasm 9.9
137 chagas disease 9.9
138 dementia 9.9
139 testicular cancer 9.9
140 gastric dilatation 9.9
141 amyloidosis 9.9
142 intracranial hypertension 9.9
143 meningitis 9.9
144 muscular dystrophy 9.9
145 pure autonomic failure 9.9
146 depression 9.9
147 seizure disorder 9.9
148 encephalopathy 9.9
149 atrial septal aneurysm 9.9
150 spondyloarthropathy 1 9.7
151 progressive familial heart block, type ia 9.7
152 breast cancer 9.7
153 diabetes mellitus, noninsulin-dependent 9.7
154 migraine with or without aura 1 9.7
155 carney complex, type 1 9.7
156 nevus, epidermal 9.7
157 sick sinus syndrome 2 9.7
158 pectus excavatum 9.7
159 pheochromocytoma 9.7
160 pulmonary hypertension, primary, 1 9.7
161 sarcoidosis 1 9.7
162 scleroderma, familial progressive 9.7
163 spondyloepimetaphyseal dysplasia, strudwick type 9.7
164 wolff-parkinson-white syndrome 9.7
165 cystic fibrosis 9.7
166 hemochromatosis, type 1 9.7
167 sjogren syndrome 9.7
168 danon disease 9.7
169 asthma 9.7
170 stroke, ischemic 9.7
171 acute insulin response 9.7
172 caronte 9.7
173 progressive familial heart block, type ib 9.7
174 anxiety 9.7
175 severe cutaneous adverse reaction 9.7
176 acute promyelocytic leukemia 9.7
177 pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis 9.7
178 muscular dystrophy, congenital, lmna-related 9.7
179 lipodystrophy, congenital generalized, type 4 9.7
180 beta-thalassemia 9.7
181 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.7
182 ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness 9.7
183 peripheral vascular disease 9.7
184 angina pectoris 9.7
185 aortic atherosclerosis 9.7
186 bartter disease 9.7
187 charcot-marie-tooth disease 9.7
188 chronic kidney failure 9.7
189 diffuse large b-cell lymphoma 9.7
190 end stage renal failure 9.7
191 glycogen storage disease 9.7
192 hepatitis 9.7
193 hepatitis b 9.7
194 leukemia 9.7
195 muscle disorders 9.7
196 pemphigus foliaceus 9.7
197 single ventricular heart 9.7
198 spinal cord injury 9.7
199 systemic scleroderma 9.7
200 thalassemia 9.7
201 traumatic brain injury 9.7
202 epidemic typhus 9.7
203 congenital generalized lipodystrophy 9.7
204 rheumatic heart disease 9.7
205 lymphoma 9.7
206 inguinal hernia 9.7
207 meningococcal meningitis 9.7
208 myofibrillar myopathy 9.7
209 thrombotic thrombocytopenic purpura 9.7
210 tooth disease 9.7
211 rabies 9.7
212 pulmonary edema 9.7
213 constrictive pericarditis 9.7
214 mitral valve insufficiency 9.7
215 hypertensive heart disease 9.7
216 guillain-barre syndrome 9.7
217 transient global amnesia 9.7
218 diarrhea 9.7
219 hairy tongue 9.7
220 glossopharyngeal neuralgia 9.7
221 lymphangioma 9.7
222 panniculitis 9.7
223 rheumatic disease 9.7
224 pericarditis 9.7
225 impotence 9.7
226 optic nerve disease 9.7
227 hyperuricemia 9.7
228 hyperinsulinism 9.7
229 dental caries 9.7
230 focal epilepsy 9.7
231 acromegaly 9.7
232 cystadenoma 9.7
233 central nervous system disease 9.7
234 purpura 9.7
235 periodontal disease 9.7
236 aortic aneurysm 9.7
237 craniopharyngioma 9.7
238 myopathy 9.7
239 neurotic disorder 9.7
240 human immunodeficiency virus infectious disease 9.7
241 kidney disease 9.7
242 agoraphobia 9.7
243 panic disorder 9.7
244 spondylitis 9.7
245 hyperthyroidism 9.7
246 interstitial myocarditis 9.7
247 myocarditis 9.7
248 influenza 9.7
249 lung disease 9.7
250 nervous system disease 9.7
251 duodenitis 9.7
252 neuropathy 9.7
253 vascular dementia 9.7
254 pemphigus 9.7
255 priapism 9.7
256 status asthmaticus 9.7
257 drug dependence 9.7
258 limb-girdle muscular dystrophy 9.7
259 juvenile hereditary hemochromatosis 9.7
260 black hairy tongue 9.7
261 bronchogenic cyst 9.7
262 chronic thromboembolic pulmonary hypertension 9.7
263 heart tumor 9.7
264 simpson-golabi-behmel syndrome 9.7
265 dysautonomia 9.7
266 head injury 9.7
267 headache 9.7
268 isolated optic neuritis 9.7
269 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.7
270 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 9.5 ANK2 KCNH2 KCNJ2 KCNQ1 RYR2 SCN5A
271 timothy syndrome 9.5 CACNA1C KCNE1 KCNH2 KCNQ1
272 heart conduction disease 9.3 KCNE1 KCNH2 KCNJ2 KCNQ1 RYR2 SCN5A
273 familial atrial fibrillation 9.3 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1 SCN5A
274 intrinsic cardiomyopathy 9.1 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1 RYR2
275 short qt syndrome 9.0 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
276 andersen cardiodysrhythmic periodic paralysis 9.0 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1

Comorbidity relations with Cardiac Arrhythmia via Phenotypic Disease Network (PDN): (showing 9, show less)


Chronic Myocardial Ischemia Familial Atrial Fibrillation
First-Degree Atrioventricular Block Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Ischemic Heart Disease Mitral Valve Disease
Sinoatrial Node Disease

Graphical network of the top 20 diseases related to Cardiac Arrhythmia:



Diseases related to Cardiac Arrhythmia

Symptoms & Phenotypes for Cardiac Arrhythmia

Human phenotypes related to Cardiac Arrhythmia:

33 (showing 2, show less)
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 33 HP:0000707
2 polymorphic and polytopic ventricular extrasystoles 33 HP:0006696

Symptoms via clinical synopsis from OMIM:

58
Cardiac:
arrhythmia
polymorphic and polytopic ventricular extrasystoles

Neuro:
syncopal attacks

Misc:
sudden death

Clinical features from OMIM:

115000

UMLS symptoms related to Cardiac Arrhythmia:


pulsus trigeminus, bigeminal pulse

MGI Mouse Phenotypes related to Cardiac Arrhythmia:

47 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.56 BVES CACNA1C GNB5 KCNH2 KCNJ2 KCNQ1
2 muscle MP:0005369 9.23 BVES CACNA1C GNB5 KCNH2 KCNJ2 KCNQ1

Drugs & Therapeutics for Cardiac Arrhythmia

Drugs for Cardiac Arrhythmia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 585, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methadone Approved, Illicit Phase 4 76-99-3 4095
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
4
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 51-43-4 5816
5
Racepinephrine Approved Phase 4,Phase 1,Not Applicable 329-65-7 838
6
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable 1951-25-3 2157
7
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
8
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
9
Milrinone Approved Phase 4,Phase 2 78415-72-2 4197
10
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-61-7 60961
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
12
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
13
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
14
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 5311068 68602
15 fluindione Approved, Investigational Phase 4,Phase 3 957-56-2
16
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
17
Bupivacaine Approved, Investigational Phase 4,Not Applicable 38396-39-3, 2180-92-9 2474
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 437-38-7 3345
19
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
20
Atropine Approved, Vet_approved Phase 4,Phase 2 5908-99-6, 51-55-8 174174
21
Ajmaline Approved, Experimental Phase 4 4360-12-7 441080
22
Procainamide Approved Phase 4,Phase 3,Not Applicable 51-06-9 4913
23
Carbetocin Approved, Investigational Phase 4,Not Applicable 37025-55-1 16681432 71715
24
Oxytocin Approved, Vet_approved Phase 4,Early Phase 1,Not Applicable 50-56-6 53477758 439302
25
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 1 35189-28-7 6540478
26
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
27
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
28
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
29
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
30
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
31
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
32
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
33
Phylloquinone Approved, Investigational Phase 4,Phase 3,Not Applicable 84-80-0
34
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
35 Menaquinone Approved, Investigational Phase 4,Phase 3,Not Applicable 1182-68-9
36
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 54678486 6691
37
Morphine Approved, Investigational Phase 4 57-27-2 5288826
38
Bisoprolol Approved Phase 4,Phase 3 66722-44-9 2405
39
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
40
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
41
Ibutilide Approved Phase 4,Phase 2,Not Applicable 122647-31-8, 122647-32-9 60753
42
Metoprolol Approved, Investigational Phase 4,Not Applicable 37350-58-6, 51384-51-1 4171
43
Magnesium oxide Approved Phase 4,Not Applicable 1309-48-4 14792
44
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68-04-2
45
Magnesium citrate Approved Phase 4,Not Applicable 3344-18-1
46
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
47
nivolumab Approved Phase 4 946414-94-4
48
Atorvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 134523-00-5 60823
49
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
50
Eplerenone Approved Phase 4,Phase 3 107724-20-9 443872 150310
51
Diltiazem Approved, Investigational Phase 4,Phase 2,Not Applicable 42399-41-7 39186
52
Dobutamine Approved Phase 4,Phase 3,Not Applicable 34368-04-2 36811
53
Enoxaparin Approved Phase 4,Phase 3 9005-49-6 772
54
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
55
Dopamine Approved Phase 4,Phase 3,Not Applicable 62-31-7, 51-61-6 681
56
Haloperidol Approved Phase 4,Phase 3,Not Applicable 52-86-8 3559
57
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
58
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 2078-54-8 4943
59
Ephedrine Approved Phase 4 299-42-3 9294
60
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
61
Phenylephrine Approved Phase 4 59-42-7 6041
62
Pseudoephedrine Approved Phase 4 90-82-4 7028
63
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
64
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
65
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
66
Nicotinamide Approved, Investigational Phase 4,Phase 2 98-92-0 936
67
Tolvaptan Approved Phase 4 150683-30-0 216237
68
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
69
Metolazone Approved Phase 4 17560-51-9 4170